Pear Therapeutics files for Chapter 11 bankruptcy

The pioneering developer of digital therapies was forced to seek protection from creditors after struggling to sell its subscription-based apps for insomnia and substance abuse.

By Elise Reuter • April 7, 2023

Navigating bankruptcy, Clovis reaches deal to sell cancer drug Rubraca

Privately held Pharma& won an auction for the ovarian and prostate cancer treatment, agreeing to pay $70 million for rights and the associated business.

By Ned Pagliarulo • April 7, 2023

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

NGM Bio lays off a third of its workforce in ‘difficult’ decision

The California biotech’s founder and chief scientific officer is also stepping down as it narrows its focus to experimental treatments for cancer and seeks new partners for other medicines.

By Kristin Jensen • April 6, 2023

A stealth biotech startup is quietly advancing a new drugmaking tool from David Liu’s lab

Public records and job postings show Resonance Medicine, which has ties to several high-profile venture capital firms, aims to reprogram protein-cutting enzymes to treat disease.

By Gwendolyn Wu • April 5, 2023

New biotech investor Cure Ventures closes first fund, raising $350M

Cure is founded by a trio of venture capitalists who have previously worked at Omega Funds, Polaris Partners and 5AM Ventures.

By Gwendolyn Wu • April 4, 2023

Biogen taps a deals expert in latest C-suite appointment

Hiring Adam Keeney, a Sanofi veteran, to lead corporate development could be seen as timely, given that dealmaking has come into focus at Biogen since the recent appointment of Chris Viehbacher as CEO.

By Jacob Bell • April 4, 2023

Seagen, Astellas win expanded FDA approval for bladder cancer drug

The first-line approval of Padcev together with Keytruda is viewed as important to expanding the drug’s market, and comes weeks after Pfizer agreed to buy Seagen for $43 billion. 

By Ned Pagliarulo • April 4, 2023

BioNTech moves into ADCs with Duality deal

The biotech is expanding its cancer medicine pipeline by licensing two experimental antibody drug conjugates from Shanghai-based Duality.

By Delilah Alvarado • April 3, 2023

Gene therapy startup Vedere to close two years after launch

The startup, a successor to a biotech that Novartis bought in 2020, will wind down after preclinical experiments didn’t meet the bar set by its leaders.

By Ben Fidler • Updated April 2, 2023

A brain drug developer joins a growing list of biotech layoffs

California-based Alector plans to reduce its headcount by around 30 as part of a larger effort to reprioritize research programs.

By Jacob Bell • March 30, 2023

Mathai Mammen, former J&J executive, to become FogPharma CEO

The veteran pharmaceutical executive was J&J’s head of R&D until his departure last August. He’s agreed to run FogPharma, a richly funded startup, and take over for founder Greg Verdine.

By Ned Pagliarulo • March 30, 2023

Bluebird, awaiting FDA feedback, says it’s likely to miss filing goal for sickle cell gene therapy

The company anticipates hearing back from the agency “within a matter of weeks,” after which it will submit a much-anticipated approval application.

By Ned Pagliarulo • March 29, 2023

A small biotech’s shares double on diabetes drug results

The stock surge has made Biomea Fusion one of the sector’s top performers among the 130 biotechs that have gone public since the start of 2021. 

By Kristin Jensen • March 29, 2023

Viking joins obesity drug development race with early study data

The biotech is working on a dual-acting weight loss treatment that could compete with medicines from Novo Nordisk, Eli Lilly and others.

By Jonathan Gardner • March 28, 2023

Novartis taps Bicycle to develop radiopharmaceutical drugs for cancer

The pharma aims to use Bicycle's drugmaking technology to explore new ways of making the targeted radiation treatments.

By Delilah Alvarado • March 28, 2023

Intra-Cellular shares rise on depression study’s success

The biotech’s drug lumateperone scored in a late-stage study of patients with either bipolar or major depressive disorder — results which some analysts called a “clear win.”

By Jacob Bell • March 28, 2023

Regeneron bets on ‘Treg’ cell therapy with Sonoma deal

The biotech will work with Sonoma, a well-funded startup run by prominent immunologist Jeffrey Bluestone, to develop cell-based medicines for ulcerative colitis and Crohn’s disease.

By Ben Fidler • March 28, 2023

After an ‘amazing year,’ SR One raises $600M to fuel more drug startups

The former venture arm of GSK had several of its portfolio companies get acquired or go public in the past year, overcoming a tough environment for young biotechs.

By Gwendolyn Wu • March 27, 2023

ALS drugmakers, encouraged by recent FDA feedback, set their sights on a key protein

A closely watched meeting showed the FDA’s own external advisers think that effects on this protein, known as neurofilament, could be enough to warrant conditional approval of certain drugs.

By Jacob Bell • Updated March 31, 2023

BrainStorm files ALS drug application over FDA protest

The medicine, a personalized stem cell treatment, will be reviewed by an FDA advisory committee sometime in the future, the company said.

By Ned Pagliarulo • March 27, 2023

Biosimilar brands bring buzz to pharma marketing

Bracing for biosimilars? Learn how biosimilar launches differ from traditional biologics.

March 27, 2023

Stuart Peltz, founder of PTC, retires after 25 years as CEO

Peltz steered PTC through several setbacks and successes, most notably the development of the spinal muscular atrophy drug Evrysdi. He'll be replaced by COO Matt Klein.

By Ned Pagliarulo • March 24, 2023

Biotech startups face ‘Series A cliff’ as venture capital stays cautious

Series A rounds have been easy to secure in the last few years, but industry watchers say they haven't seen a corresponding increase in Series Bs as startups struggle to recruit new investors.

By Gwendolyn Wu • Updated March 27, 2023

Former Seagen CEO Siegall returns to biotech as head of early-stage startup

Nearly one year after Clay Siegall’s arrest and resignation from Seagen, the executive has been named CEO of Morphimmune, a small cancer biotech.

By Ned Pagliarulo • March 23, 2023

Novo partners with Dewpoint to mine an emerging field for new drugs

The companies will collaborate to identify compounds that could treat insulin resistance by targeting shape-shifting cellular droplets known as biomolecular condensates.

By Delilah Alvarado • March 22, 2023